ArticleThe Journal of clinical endocrinology and metabolism2022
Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study.
Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Incidental discovery of a non-secreting bladder paraganglioma: A case report.Urology case reports · 2026Article
- Paraganglioma of the urinary bladder: A case report and discussion of the literature.Urology case reports · 2026Article
- Bladder paraganglioma with lymph node metastasis treated by surgery with long-term recurrence-free survival: A case report.Urology case reports · 2026Article
- Recurrent bladder paraganglioma with peritoneal dissemination: An unusual pattern of metastatic progression. Case report and literature review.Urology case reports · 2026Article
- Temozolomide as neoadjuvant therapy for bladder paraganglioma.Endocrine · 2025Article
- Genetics of urinary bladder paragangliomas: a multi-center study of a Chinese cohort.Journal of endocrinological investigation · 2025Article
- Metastatic Malignant Paraganglioma of Rare Sites Failed on Conventional Treatments Demonstrating Beneficial Response toWorld journal of nuclear medicine · 2025Article
- Incidentally Detected Urinary Bladder Paraganglioma.JCEM case reports · 2025Article
- Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review.Frontiers in medicine · 2025Article
- Case Report: Solving a decade-long paroxysmal hypertension mystery: bladder paraganglioma.Frontiers in oncology · 2025Article
- Bladder paraganglioma: a 25-year systematic review unveils the benefits of early diagnosis in reducing surgical complications.Frontiers in surgery · 2025Article
- Urinary bladder paraganglioma presenting with abdominal pain and elevated cardiac enzymes: a case report of atypical manifestations and diagnostic challenges.Frontiers in oncology · 2025Article
- A rare case of bladder paraganglioma treated successfully with robotic partial cystectomy.Endocrine oncology (Bristol, England) · 2025Article
- Unrecognised paraganglioma of the urinary bladder precipitating hypertensive crisis.BMJ case reports · 2024Article
- Non-functional muscle-invasive bladder paraganglioma-a case report.AME case reports · 2024Article
- Case report: A novel somaticFrontiers in endocrinology · 2024Article
- Metastatic paraganglioma presenting with spinal cord compression requiring urgent surgery.BMJ case reports · 2023Article
- Bladder Paraganglioma Associated With Succinate Dehydrogenase A Mutation Presenting as Pelvic Pain.JCEM case reports · 2023Article
- Case Report: Octreotide plus CVD chemotherapy for the treatment of multiple metastatic paragangliomas after double resection for functional bladder paraganglioma and urothelial papilloma.Frontiers in oncology · 2022Article
- Bladder Paraganglioma Presenting as Post-Micturition Syncope.European journal of case reports in internal medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 5 countries.
Funding
Abstract
contextUrinary bladder paraganglioma (UBPGL) is rare.
objectiveWe aimed to characterize the presentation and outcomes of patients diagnosed with UBPGL.
methodsWe conducted a multicenter study of consecutive patients with pathologically confirmed UBPGL evaluated between 1971 and 2021. Outcomes included repeat bladder surgery, metastases, and disease-specific mortality.
resultsPatients (n=110 total; n=56 [51%] women) were diagnosed with UBPGL at a median age of 50 years (interquartile range [IQR], 36-61 years). Median tumor size was 2 cm (IQR, 1-4 cm). UBPGL was diagnosed prior to biopsy in only 37 (34%), and only 69 (63%) patients had evaluation for catecholamine excess. In addition to the initial bladder surgery, 26 (25%) required multiple therapies, including repeat surgery in 10 (9%). Synchronous metastases were present in 9 (8%) patients, and 24 (22%) other patients with UBPGL developed metachronous metastases at a median of 4 years (IQR, 2-10 years) after the initial diagnosis. Development of metachronous metastases was associated with younger age (hazard ratio [HR] 0.97; 95% CI, 0.94-0.99), UBPGL size (HR 1.69; 95% CI, 1.31-2.17), and a higher degree of catecholamine excess (HR 5.48; 95% CI, 1.40-21.39). Disease-specific mortality was higher in patients with synchronous metastases (HR 20.80; 95% CI, 1.30-332.91). Choice of initial surgery, genetic association, sex, or presence of muscular involvement on pathology were not associated with development of metastases or mortality.
conclusionsOnly a minority of patients were diagnosed before biopsy/surgery, reflecting need for better diagnostic strategies. All patients with UBPGL should have lifelong monitoring for development of recurrence and metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.